BiotechTube
Laurus Labs

Laurus Labs

LAURUSLABS.NSApproved
Hyderabad, IndiaFounded 20054000-5000 employeeslauruslabs.com

Laurus Labs is a vertically integrated pharmaceutical company based in Hyderabad, India, with a significant global presence in the API and generic formulations market. It has established itself as a key player in the global supply of HIV/AIDS drugs and has strategically expanded into high-growth areas like oncology, cardiology, and diabetes. The company leverages its strong R&D and manufacturing capabilities to serve both regulated and emerging markets, with a growing CDMO business catering to innovator companies worldwide.

Market Cap
$5.5B
+56.3% period
Pipeline
—
Patents
20
granted
Publications
2
indexed

LAURUSLABS.NS · Stock Price

USD 961.40+346.25 (+56.29%)

Historical price data

AI Company Overview

Laurus Labs is a vertically integrated pharmaceutical company based in Hyderabad, India, with a significant global presence in the API and generic formulations market. It has established itself as a key player in the global supply of HIV/AIDS drugs and has strategically expanded into high-growth areas like oncology, cardiology, and diabetes. The company leverages its strong R&D and manufacturing capabilities to serve both regulated and emerging markets, with a growing CDMO business catering to innovator companies worldwide.

HIV/AIDSOncologyCardiovascularMetabolic DisordersCentral Nervous System

Technology Platform

Advanced chemical synthesis, process development, and scale-up manufacturing for Active Pharmaceutical Ingredients (APIs) and formulations, with growing capabilities in biosimilars and contract development and manufacturing (CDMO).

Funding History

2
Total raised:$250M
PIPE$100MJul 15, 2020
IPO$150MDec 21, 2016

FDA Approved Drugs

23
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATEANDAMar 4, 2026
FLUCYTOSINEANDAJul 23, 2025
SACUBITRIL AND VALSARTANANDAMay 28, 2024

Opportunities

Significant growth opportunities exist in the oncology generics market driven by patent expiries, expansion of the high-margin CDMO business with global innovators, and the long-term potential of the biosimilars pipeline.
Increasing penetration in regulated markets and emerging economies also presents substantial avenues for growth.

Risk Factors

Key risks include intense pricing pressure in the generic pharmaceuticals market, regulatory compliance challenges with agencies like the US FDA, dependence on key starting materials from specific regions, and execution risks associated with scaling new business segments like biosimilars and complex injectables.

Competitive Landscape

Laurus Labs competes with major Indian pharma companies like Sun Pharma, Dr. Reddy's, and Aurobindo in generics, and with global/CDMO players like Lonza. Its differentiation is built on deep ARV expertise, vertical integration, and a strategic shift towards complex chemistry and CDMO services to move up the value chain.